Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Mar 09 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Erythromycin Tablets USP in two dosages. These tablets are used to treat various infections, including respiratory and skin infections. The manufacturing will take place at Zydus's facility in Moraiya, Ahmedabad.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 09, 2023, titled "Zydus receives final approval from the USFDA forErythromycin Tablets USP, 250 mg and 500 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases